Department of Radiation Oncology at Fox Chase Cancer Center Welcomes New Physician
PHILADELPHIA (June 28, 2004) - Mark K. Buyyounouski has joined Fox Chase Cancer Center as an associate member of the medical science division and an attending physician in the department of radiation oncology.
Buyyounouski's chief research interest has been in the field of prostate cancer, on which he has given several local, national and international presentations. Buyyounouski is a co-primary investigator of an ongoing Phase III randomized trial at Fox Chase that tests an erectile tissue-sparing technique using intensity-modulated radiation therapy (IMRT). IMRT is a sophisticated type of treatment that can deliver radiation to cancer tissues while avoiding normal tissues and limiting toxicity.
Buyyounouski will also care for patients with lung and brain cancer. Other areas of expertise include stereotactic radiotherapy and prostate brachytherapy. The radiation oncology department at Fox Chase has a long tradition of developing and instituting the most modern technology into radiation therapy, such as ultrasound, CT and MRI.
While at Fox Chase, Buyyounouski plans to investigate highly targeted, image-guided radiotherapy techniques that improve cancer control. Novel imaging agents used with MRI or PET scanning can be used for designing radiation treatments, and he plans to help better define their role in the everyday care of cancer patients.
Buyyounouski received a bachelor's degree in physics from Lafayette College in Easton, Pa., and a master's degree in medical physics from Columbia University. He completed his M.D. at the New Jersey Medical School of the University of Medicine and Dentistry of New Jersey.
In 2001, after completing his internship in internal medicine at Saint Barnabas Medical Center in Livingston, N.J., he entered the radiation oncology residency program at Fox Chase. During his residency he was twice awarded the Radiological Society of North America Roentgen Resident/Fellow Research Award that recognizes and encourages outstanding residents and fellows in radiologic research.
Fox Chase Cancer Center, part of Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase also was among the first institutions to receive the National Cancer Institute’s prestigious comprehensive cancer center designation in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are routinely recognized in national rankings, and the Center’s nursing program has achieved Magnet status for excellence three consecutive times. Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research and oversees programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE (1-888-369-2427).